191 related articles for article (PubMed ID: 32615971)
21. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).
Brookman-May S; May M; Shariat SF; Xylinas E; Stief C; Zigeuner R; Chromecki T; Burger M; Wieland WF; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Feciche B; Truss M; Gilfrich C; Pahernik S; Hohenfellner M; Zastrow S; Wirth MP; Novara G; Carini M; Minervini A; Simeone C; Antonelli A; Mirone V; Longo N; Simonato A; Carmignani G; Ficarra V;
Eur Urol; 2013 Sep; 64(3):472-7. PubMed ID: 22748912
[TBL] [Abstract][Full Text] [Related]
22. Overall survival and development of stage IV chronic kidney disease in patients undergoing partial and radical nephrectomy for benign renal tumors.
Kaushik D; Kim SP; Childs MA; Lohse CM; Costello BA; Cheville JC; Boorjian SA; Leibovich BC; Thompson RH
Eur Urol; 2013 Oct; 64(4):600-6. PubMed ID: 23280319
[TBL] [Abstract][Full Text] [Related]
23. Renal cell carcinoma in the solitary kidney: an analysis of complications and outcome after nephron sparing surgery.
Ghavamian R; Cheville JC; Lohse CM; Weaver AL; Zincke H; Blute ML
J Urol; 2002 Aug; 168(2):454-9. PubMed ID: 12131287
[TBL] [Abstract][Full Text] [Related]
24. Comparing Outcomes for Patients with Clinical T1b Renal Cell Carcinoma Treated With Either Percutaneous Microwave Ablation or Surgery.
Shapiro DD; Wells SA; Best SL; Hedican SP; Ziemlewicz TJ; Lubner MG; Hinshaw JL; Lee FT; Jarrard DF; Richards KA; Downs TM; Allen GO; Nakada SY; Abel EJ
Urology; 2020 Jan; 135():88-94. PubMed ID: 31585198
[TBL] [Abstract][Full Text] [Related]
25. Oncologic outcomes of patients with positive surgical margin after partial nephrectomy: a 25-year single institution experience.
Petros FG; Metcalfe MJ; Yu KJ; Keskin SK; Fellman BM; Chang CM; Gu C; Tamboli P; Matin SF; Karam JA; Wood CG
World J Urol; 2018 Jul; 36(7):1093-1101. PubMed ID: 29488096
[TBL] [Abstract][Full Text] [Related]
26. Partial versus Radical Nephrectomy for T1-T2 Renal Cell Carcinoma in Patients with Chronic Kidney Disease Stage III: a Multiinstitutional Analysis of Kidney Function and Survival Rate.
Chung JS; Son NH; Lee SE; Hong SK; Jeong CW; Kwak C; Kim HH; Hong SH; Kim YJ; Kang SH; Chung J; Kwon TG; Hwang EC; Byun SS
J Korean Med Sci; 2018 Oct; 33(43):e277. PubMed ID: 30344463
[TBL] [Abstract][Full Text] [Related]
27. Survival after partial and radical nephrectomy for the treatment of stage T1bN0M0 renal cell carcinoma (RCC) in the USA: a propensity scoring approach.
Badalato GM; Kates M; Wisnivesky JP; Choudhury AR; McKiernan JM
BJU Int; 2012 May; 109(10):1457-62. PubMed ID: 21933334
[TBL] [Abstract][Full Text] [Related]
28. Elective partial nephrectomy is equivalent to radical nephrectomy in patients with clinical T1 renal cell carcinoma: results of a retrospective, comparative, multi-institutional study.
Antonelli A; Ficarra V; Bertini R; Carini M; Carmignani G; Corti S; Longo N; Martorana G; Minervini A; Mirone V; Novara G; Serni S; Simeone C; Simonato A; Siracusano S; Volpe A; Zattoni F; Cunico SC;
BJU Int; 2012 Apr; 109(7):1013-8. PubMed ID: 21883829
[TBL] [Abstract][Full Text] [Related]
29. Comparison of long-term results after nephron-sparing surgery and radical nephrectomy in treating 4- to 7-cm renal cell carcinoma.
Milonas D; Skulčius G; Baltrimavičius R; Auškalnis S; Kinčius M; Matjošaitis A; Gudinavičienė I; Smailytė G; Jievaltas M
Medicina (Kaunas); 2013; 49(5):223-8. PubMed ID: 24247918
[TBL] [Abstract][Full Text] [Related]
30. Nephron-sparing surgery is superior to radical nephrectomy in preserving renal function benefit even when expanding indications beyond the traditional 4-cm cutoff.
Pignot G; Bigot P; Bernhard JC; Bouliere F; Bessede T; Bensalah K; Salomon L; Mottet N; Bellec L; Soulié M; Ferrière JM; Pfister C; Drai J; Colombel M; Villers A; Rigaud J; Bouchot O; Montorsi F; Bertini R; Belldegrun AS; Pantuck AJ; Patard JJ
Urol Oncol; 2014 Oct; 32(7):1024-30. PubMed ID: 24996775
[TBL] [Abstract][Full Text] [Related]
31. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma.
Van Poppel H; Da Pozzo L; Albrecht W; Matveev V; Bono A; Borkowski A; Colombel M; Klotz L; Skinner E; Keane T; Marreaud S; Collette S; Sylvester R
Eur Urol; 2011 Apr; 59(4):543-52. PubMed ID: 21186077
[TBL] [Abstract][Full Text] [Related]
32. Surgical Approach Does Not Impact Margin Status After Partial Nephrectomy for Large Renal Masses.
Ayangbesan A; Golombos DM; Golan R; O'Malley P; Lewicki P; Wu X; Scherr DS
J Endourol; 2019 Jan; 33(1):50-60. PubMed ID: 29914269
[TBL] [Abstract][Full Text] [Related]
33. Overall survival and renal function after partial and radical nephrectomy among older patients with localised renal cell carcinoma: a propensity-matched multicentre study.
Chung JS; Son NH; Lee SE; Hong SK; Lee SC; Kwak C; Hong SH; Kim YJ; Kang SH; Byun SS
Eur J Cancer; 2015 Mar; 51(4):489-497. PubMed ID: 25576517
[TBL] [Abstract][Full Text] [Related]
34. Compared with radical nephrectomy, nephron-sparing surgery offers a long-term survival advantage in patients between the ages of 20 and 44 years with renal cell carcinomas (≤4 cm): an analysis of the SEER database.
Daugherty M; Bratslavsky G
Urol Oncol; 2014 Jul; 32(5):549-54. PubMed ID: 24495447
[TBL] [Abstract][Full Text] [Related]
35. Nephron-sparing surgery for renal cell carcinoma: clinicopathologic features predictive of patient outcome.
Krejci KG; Blute ML; Cheville JC; Sebo TJ; Lohse CM; Zincke H
Urology; 2003 Oct; 62(4):641-6. PubMed ID: 14550434
[TBL] [Abstract][Full Text] [Related]
36. Is Robotic Partial Nephrectomy Safe for T3a Renal Cell Carcinoma? Experience of a High-Volume Center.
Andrade HS; Zargar H; Akca O; Kara O; Caputo PA; Ramirez D; Andrés G; Stein RJ; Chueh SJ; Kaouk JH
J Endourol; 2017 Feb; 31(2):153-157. PubMed ID: 27881027
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of perirenal and/or sinus fat infiltration in patients with pT3a renal cell carcinoma: A multicentre cohort study. LARCG Group.
García Marchiñena P; Tobia I; Abreu D; de Cássio Zequi S; Jurado A; Gueglio G;
Actas Urol Esp (Engl Ed); 2019 Nov; 43(9):495-502. PubMed ID: 31155375
[TBL] [Abstract][Full Text] [Related]
38. Time to recurrence is a significant predictor of cancer-specific survival after recurrence in patients with recurrent renal cell carcinoma--results from a comprehensive multi-centre database (CORONA/SATURN-Project).
Brookman-May SD; May M; Shariat SF; Novara G; Zigeuner R; Cindolo L; De Cobelli O; De Nunzio C; Pahernik S; Wirth MP; Longo N; Simonato A; Serni S; Siracusano S; Volpe A; Morgia G; Bertini R; Dalpiaz O; Stief C; Ficarra V; ; ;
BJU Int; 2013 Nov; 112(7):909-16. PubMed ID: 23890378
[TBL] [Abstract][Full Text] [Related]
39. Partial nephrectomy for renal masses ≥ 7 cm: technical, oncological and functional outcomes.
Long CJ; Canter DJ; Kutikov A; Li T; Simhan J; Smaldone M; Teper E; Viterbo R; Boorjian SA; Chen DY; Greenberg RE; Uzzo RG
BJU Int; 2012 May; 109(10):1450-6. PubMed ID: 22221502
[TBL] [Abstract][Full Text] [Related]
40. Predictors of oncological outcome after resection of locally recurrent renal cell carcinoma.
Margulis V; McDonald M; Tamboli P; Swanson DA; Wood CG
J Urol; 2009 May; 181(5):2044-51. PubMed ID: 19286220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
